Immunocore is the latest to nab a private placement, securing $140M to pursue more TCR R&D

Looking to secure a fresh raise to invigorate R&D, Immunocore is putting together a PIPE.

The former Medigene spinout, six months after the FDA approved its TCR drug tebentafusp, put out word Monday that it’s selling just over 3.7 million shares of company stock at $37.50 each. This is going to certain investors as a PIPE financing for a total of $140 million.